Matches in Wikidata for { <http://www.wikidata.org/entity/Q88645131> ?p ?o ?g. }
- Q88645131 description "artículu científicu espublizáu en mayu de 2018" @default.
- Q88645131 description "im Mai 2018 veröffentlichter wissenschaftlicher Artikel" @default.
- Q88645131 description "scientific article published on 08 May 2018" @default.
- Q88645131 description "wetenschappelijk artikel" @default.
- Q88645131 description "наукова стаття, опублікована в травні 2018" @default.
- Q88645131 name "Gemcitabine-oxaliplatin plus rituximab (R-GemOx) as first-line treatment in elderly patients with diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 trial" @default.
- Q88645131 name "Gemcitabine-oxaliplatin plus rituximab (R-GemOx) as first-line treatment in elderly patients with diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 trial" @default.
- Q88645131 type Item @default.
- Q88645131 label "Gemcitabine-oxaliplatin plus rituximab (R-GemOx) as first-line treatment in elderly patients with diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 trial" @default.
- Q88645131 label "Gemcitabine-oxaliplatin plus rituximab (R-GemOx) as first-line treatment in elderly patients with diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 trial" @default.
- Q88645131 prefLabel "Gemcitabine-oxaliplatin plus rituximab (R-GemOx) as first-line treatment in elderly patients with diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 trial" @default.
- Q88645131 prefLabel "Gemcitabine-oxaliplatin plus rituximab (R-GemOx) as first-line treatment in elderly patients with diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 trial" @default.
- Q88645131 P1433 Q88645131-1B7106E8-83F4-4721-8C83-76B6BE6FA48B @default.
- Q88645131 P1476 Q88645131-B44128A2-9145-4509-AC5F-2B55CF499876 @default.
- Q88645131 P2093 Q88645131-192D9173-4FB4-4EC9-9EBC-1C5245630723 @default.
- Q88645131 P2093 Q88645131-19B83C77-C671-43EB-8F12-55128086363D @default.
- Q88645131 P2093 Q88645131-2ACE2C2D-0540-4BA9-9A1A-F402E47CBAC4 @default.
- Q88645131 P2093 Q88645131-4E6F30BF-0C39-49B6-8559-E4F2A4A4DF37 @default.
- Q88645131 P2093 Q88645131-781C38A4-72E9-4294-9072-E0BE89FC0930 @default.
- Q88645131 P2093 Q88645131-92D7BF35-050B-4C08-8B36-957ED1218606 @default.
- Q88645131 P2093 Q88645131-97471351-2C59-4B6C-A34D-7593887B797C @default.
- Q88645131 P2093 Q88645131-A2395929-C1C1-4444-A41B-C5ABFC0A17B8 @default.
- Q88645131 P2093 Q88645131-D0DEF729-8F22-43BD-97ED-D0ED187D12A6 @default.
- Q88645131 P2093 Q88645131-DF1BDC48-DAE6-4323-9883-5B1FE1FAD242 @default.
- Q88645131 P2860 Q88645131-0C46D9D9-11C5-4DB3-AC87-13799007F985 @default.
- Q88645131 P2860 Q88645131-220F9B4F-1EC3-43A4-877C-2B5D05FC3071 @default.
- Q88645131 P2860 Q88645131-226B04BE-C345-4542-8D74-3C87C89AED84 @default.
- Q88645131 P2860 Q88645131-25FA8AAB-1037-4782-BB9B-6386AEAE7E50 @default.
- Q88645131 P2860 Q88645131-2EDEFF7E-6999-4599-BA82-F29FF5925218 @default.
- Q88645131 P2860 Q88645131-32ADA4EC-E90B-4A10-A310-F6A203A99256 @default.
- Q88645131 P2860 Q88645131-3EB35CC7-F8A7-493B-980E-A67D695FDE75 @default.
- Q88645131 P2860 Q88645131-449EEBC1-D341-49BA-B7B0-B1E9ED31D01F @default.
- Q88645131 P2860 Q88645131-54F2AF66-6306-49BE-ABC0-A5DD0C0F10D0 @default.
- Q88645131 P2860 Q88645131-5A2C822D-F54E-4A9E-A621-F6044DFF8659 @default.
- Q88645131 P2860 Q88645131-5E9691DC-930F-4448-BA61-0C83802912BB @default.
- Q88645131 P2860 Q88645131-63801058-F2D1-449B-8951-A150C4524FE9 @default.
- Q88645131 P2860 Q88645131-77728D6C-1DC2-4EC2-9BBB-C9AADC2762D8 @default.
- Q88645131 P2860 Q88645131-7CD776BD-56BF-441A-8524-0F7EFCA7FA2F @default.
- Q88645131 P2860 Q88645131-84C532A3-BDDB-4CDC-B052-598D9C487262 @default.
- Q88645131 P2860 Q88645131-8802B215-E947-4AC9-872E-7A4919ABB790 @default.
- Q88645131 P2860 Q88645131-96945C6B-904F-4B1E-BF92-77360A997F8F @default.
- Q88645131 P2860 Q88645131-99F2BAB6-B78D-4236-A317-6E84252AB0FB @default.
- Q88645131 P2860 Q88645131-9B863EFA-D982-4DE9-8E92-1E9235BB6D10 @default.
- Q88645131 P2860 Q88645131-9DC60818-F0C0-4395-9002-AEB5CE721886 @default.
- Q88645131 P2860 Q88645131-B15BA911-210F-4F02-86B1-A0B8454AEFB4 @default.
- Q88645131 P2860 Q88645131-BAD7E8B9-EC9C-488B-A357-F9177BE60CA9 @default.
- Q88645131 P2860 Q88645131-BC8F578B-FEC9-43CD-AD24-17B86427E4B6 @default.
- Q88645131 P2860 Q88645131-C026E719-8F34-40BD-AB0E-56C659AE4C44 @default.
- Q88645131 P2860 Q88645131-D2A4E7C7-D810-4CD0-9BB6-AF733A5BA639 @default.
- Q88645131 P2860 Q88645131-D7AE06EB-B981-4480-BE31-0D6BE8023167 @default.
- Q88645131 P2860 Q88645131-D91A1FBC-34AA-4895-9AF9-4335877822F3 @default.
- Q88645131 P2860 Q88645131-D9CE6EB0-25CB-4596-9CE2-D50D5932C656 @default.
- Q88645131 P2860 Q88645131-DBC8E751-74EE-4F35-BF5A-8C981D547A8E @default.
- Q88645131 P2860 Q88645131-E2D4B5FB-6D96-4330-B176-D0B09D3E24DF @default.
- Q88645131 P2860 Q88645131-FAC3E02A-32B0-4810-8B23-B10D1FDB1E62 @default.
- Q88645131 P2860 Q88645131-FF0E9563-63C8-4397-9C60-F9B51FD76E74 @default.
- Q88645131 P304 Q88645131-A1CB60FD-BEFE-4A06-A0AB-7CB8D9353507 @default.
- Q88645131 P31 Q88645131-3F9AF975-1392-463E-8952-FA4582A1057B @default.
- Q88645131 P356 Q88645131-2A390675-1A94-4BB3-9521-FD47A8EA6F2E @default.
- Q88645131 P433 Q88645131-ADE2763C-3D00-4B0F-8E4E-425A4437BDA7 @default.
- Q88645131 P478 Q88645131-73DFFEB2-0513-4D79-AF8A-D010CEB42357 @default.
- Q88645131 P577 Q88645131-758524A2-E8CC-40A0-B86F-B5D9D8653867 @default.
- Q88645131 P698 Q88645131-6F092E54-A2B4-41A3-A9F9-FDA74AB1696D @default.
- Q88645131 P921 Q88645131-5BCC74A2-4940-4964-9A31-3613E9035DBF @default.
- Q88645131 P921 Q88645131-5E032DD6-3A57-4274-A369-23446FF1D060 @default.
- Q88645131 P921 Q88645131-A011EE73-65DA-4F35-8763-C39EF13D0E50 @default.
- Q88645131 P921 Q88645131-A10411D5-5874-486C-B39D-8CCDCD8F9F1A @default.
- Q88645131 P921 Q88645131-BE02DCB6-597B-44AD-9861-0AF2E6C7DC13 @default.
- Q88645131 P356 S2352-3026(18)30054-1 @default.
- Q88645131 P698 29752199 @default.
- Q88645131 P1433 Q26840042 @default.
- Q88645131 P1476 "Gemcitabine-oxaliplatin plus rituximab (R-GemOx) as first-line treatment in elderly patients with diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 trial" @default.
- Q88645131 P2093 "Hua-Yuan Zhu" @default.
- Q88645131 P2093 "Jian-Yong Li" @default.
- Q88645131 P2093 "Jin-Hua Liang" @default.
- Q88645131 P2093 "Lei Cao" @default.
- Q88645131 P2093 "Lei Fan" @default.
- Q88645131 P2093 "Li Wang" @default.
- Q88645131 P2093 "Qiu-Dan Shen" @default.
- Q88645131 P2093 "Wei Wu" @default.
- Q88645131 P2093 "Wei Xu" @default.
- Q88645131 P2093 "Yi Xia" @default.
- Q88645131 P2860 Q28088365 @default.
- Q88645131 P2860 Q28204313 @default.
- Q88645131 P2860 Q28251216 @default.
- Q88645131 P2860 Q28271344 @default.
- Q88645131 P2860 Q30235296 @default.
- Q88645131 P2860 Q30975765 @default.
- Q88645131 P2860 Q33341057 @default.
- Q88645131 P2860 Q34742742 @default.
- Q88645131 P2860 Q35247997 @default.
- Q88645131 P2860 Q35673260 @default.
- Q88645131 P2860 Q37146688 @default.
- Q88645131 P2860 Q37273186 @default.
- Q88645131 P2860 Q38075871 @default.
- Q88645131 P2860 Q38838789 @default.
- Q88645131 P2860 Q40318856 @default.
- Q88645131 P2860 Q40678767 @default.
- Q88645131 P2860 Q43004464 @default.
- Q88645131 P2860 Q43223088 @default.